Form 4: Nathalie Dubois-Stringfellow Sells Sangamo Therapeutics Stock

Nathalie Dubois-Stringfellow, SVP-Chief Development Officer at Sangamo Therapeutics, reported a sale of common stock on April 21, 2026.

Summary

• Nathalie Dubois-Stringfellow, an officer of Sangamo Therapeutics, Inc., sold 345,942 shares of common stock on April 21, 2026.
• The sale was executed at a weighted-average price of $0.2578 per share, with individual transactions ranging from $0.2533 to $0.2634.
• Following the transaction, Dubois-Stringfellow beneficially owns 332,769 shares of common stock directly.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of stock by a key executive, although it is a standard disclosure and does not inherently indicate negative company performance.

Negatives

• A significant number of shares (345,942) were sold by a key executive.

Future Outlook

No forward-looking statements or guidance are present in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings, like this one from Sangamo Therapeutics, are standard disclosures for insider transactions. Such sales by executives can sometimes be interpreted by the market, though the reasons for individual sales can vary widely.

Stakeholder Impact

• Shareholders may view the sale of a large number of shares by an executive with concern, potentially impacting investor sentiment.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Trading, Stock Sale, Executive Officer, Common Stock